The role of biologically effective dose (BED) in clinical oncology.
about
Modern Radiotherapy Concepts and the Impact of Radiation on Immune ActivationHypofractionated whole breast radiotherapy: current perspectivesIncreased Biological Effective Dose of Radiation Correlates with Prolonged Survival of Patients with Limited-Stage Small Cell Lung Cancer: A Systematic Review.Fractionated Stereotactic Gamma Knife Radiosurgery for Large Brain Metastases: A Retrospective, Single Center Study.Human Lung Cancer Risks from Radon - Part III - Evidence of Influence of Combined Bystander and Adaptive Response Effects on Radon Case-Control Studies - A Microdose Analysis.Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature.The dosimetric comparison of the radiotherapeutic plans between composite and synchronous planning approaches in sequential IMRT for nasopharyngeal carcinoma.21 years of biologically effective doseNon-melanoma skin cancer treated with high-dose-rate brachytherapy and Valencia applicator in elderly patients: a retrospective case seriesComparison of breast sequential and simultaneous integrated boost using the biologically effective dose volume histogram (BEDVH)The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trialElectronic brachytherapy for superficial and nodular basal cell carcinoma: a report of two prospective pilot trials using different dosesImpact of hypofractionation and tangential beam IMRT on the acute skin reaction in adjuvant breast cancer radiotherapy.Mucosal melanoma of the head and neck: a population-based study from Slovenia, 1985-2013.The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.Predictive parameters in hypofractionated whole-breast 3D conformal radiotherapy according to the Ontario Canadian trial.Role of radiotherapy in melanoma managementHigh-dose-rate interstitial brachytherapy in head and neck cancer: do we need a look back into a forgotten art - a single institute experience.Assessment of Radiobiological α/β Ratio in Lung Cancer and Fibroblast Cell Lines Using Viability Assays.Why RBE must be a variable and not a constant in proton therapy.Predictive value of modelled tumour control probability based on individual measurements of in vitro radiosensitivity and potential doubling time.Radiation physiology - evidence for a higher biological effect of 24 Gy in four fractions as compared to three.Clinical significance of cumulative biological effective dose and overall treatment time in the treatment of carcinoma cervix.Using state variables to model the response of tumour cells to radiation and heat: a novel multi-hit-repair approach.The developing role for intensity-modulated radiation therapy (IMRT) in the non-surgical treatment of brain metastasesProton radiobiology and its clinical implications.Low and medium doses of hypofractionated stereotactic radiotherapy could be suboptimal for early-stage lung cancer.Quantitative assessment of radiation dose and fractionation effects on normal tissue by utilizing a novel lung fibrosis index model.Practical aspects and uncertainty analysis of biological effective dose (BED) regarding its three-dimensional calculation in multiphase radiotherapy treatment plans.Providing a fast conversion of total dose to biological effective dose (BED) for hybrid seed brachytherapy.Radiobiological compensation of treatment errors in radiotherapy.Biologically effective dose using reciprocal repair for varying fraction doses and fraction intervals.Calculation of high-LET radiotherapy dose required for compensation of overall treatment time extensions.The potential for mathematical modelling in the assessment of the radiation dose equivalent of cytotoxic chemotherapy given concomitantly with radiotherapy.Temporally feathered intensity modulated radiation therapy: a planning technique to reduce normal tissue toxicity.Cardiac radiation dose distribution, cardiac events and mortality in early-stage lung cancer treated with stereotactic body radiation therapy (SBRT).Re-irradiation volumetric modulated arc therapy optimization based on cumulative biologically effective dose objectivesBreast size impact on adjuvant radiotherapy adverse effects and dose parameters in treatment planning
P2860
Q26744490-276B8606-D692-4F31-8AE3-1FB3941317C7Q26775841-FEC43C4F-DBDB-49B7-B9A6-65E03CC28D28Q36030323-77757137-19A5-490F-8444-40AFAC4FE94FQ36142586-7B65F912-43C6-430C-80E6-65E157C45858Q36197741-BC5F231C-63AD-499C-9500-A33D3E1A40ADQ36258234-8EE27CC3-9E7B-4FE0-87EA-67EFFDBFFF84Q36317773-E4112BDD-F0F1-47C2-9177-B86912EAEEFEQ36324701-8950782F-CBD3-4930-A267-A2DD6EDE69C9Q36471856-46403621-DAC4-4B1A-A564-463A4915D68BQ36529659-CC6EAE1F-4F84-4A82-9DC1-F2E6B5E598B1Q36571627-E5907415-C77F-44CA-B892-561A1C7ACB84Q36690526-70EE10A7-4525-42C3-BDCC-3CEFD840B62EQ37139905-7D25D625-9B86-4606-B74F-1DB0FF5705ECQ37340883-3DDF4A80-6D70-433C-972D-CE334BE4AE7AQ37644237-A3D98D5A-D0A8-4189-AF33-9336E1FC5765Q37730573-17D2004A-2667-498F-9BF3-9F90B6B72C3EQ38039069-70EBB046-025A-4F81-9E12-2430F90BC548Q38431076-D6C77FF7-B035-43D7-961B-B8FEC494F392Q38709593-2749E577-5334-4321-B490-9A3BCB8E6441Q39794527-C9510609-5649-42D9-8F0D-002171CF24A3Q40094376-0B66E440-0E05-4B26-B8FA-4EEFFD1E33D0Q40256868-1C897E57-A9EB-44CA-9C14-D61BB860BAE9Q41116793-82D63AFF-EF42-41C2-8160-44721E650007Q41771762-04CEB64F-4B88-4061-8E9B-1B751A49A9F8Q42420422-D6BD6507-1A65-4F0A-BA5B-8622D22015E3Q44979068-3DAD3BBC-C40D-4E33-8453-F847F13C193CQ47149089-60D16B51-407B-4A2E-B7F2-1C80C6091397Q47153259-69C6C589-4B1A-4B3B-A436-5E5335DCC02BQ51070703-D44064F9-F1D4-4040-B2C4-8C5E0E96F8D1Q51326107-0977451C-4639-4D45-88D4-329FF983FA70Q51896437-EB0AEFB7-B793-4B66-84BB-4453264A88DEQ51898724-E663E3BA-FB85-4411-B1F0-75307EF9C332Q51949252-9251F621-C703-4963-AE11-4B643C9E48ADQ51964012-4682E5C9-D809-4B1B-91CB-44CCB2C6B6DCQ54203051-33224299-A221-4060-AC0D-633DE623C1E9Q55016424-596C12ED-6746-4F56-B9AD-EF929606B6BCQ58103863-2C587917-3B36-4F38-8DE5-313298085FFEQ58802743-D8DED350-A9BD-4FC6-94C9-2D2AFFC3D283
P2860
The role of biologically effective dose (BED) in clinical oncology.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The role of biologically effective dose (BED) in clinical oncology.
@ast
The role of biologically effective dose (BED) in clinical oncology.
@en
The role of biologically effective dose
@nl
type
label
The role of biologically effective dose (BED) in clinical oncology.
@ast
The role of biologically effective dose (BED) in clinical oncology.
@en
The role of biologically effective dose
@nl
prefLabel
The role of biologically effective dose (BED) in clinical oncology.
@ast
The role of biologically effective dose (BED) in clinical oncology.
@en
The role of biologically effective dose
@nl
P2093
P356
P1433
P1476
The role of biologically effective dose (BED) in clinical oncology.
@en
P2093
P356
10.1053/CLON.2001.9221
P577
2001-01-01T00:00:00Z